Orion Corporation: Managers’ Transactions Overview
Orion Corporation has received a disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Manager Details
Name: Liisa Hurme
Position: Chief Executive Officer
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 74913/13/8
Transaction Information
Details of transactions reported are as follows:
NASDAQ HELSINKI LTD (XHEL)
Transaction date: Not specified
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details:
(1): Volume: 5 Unit price: 46.7 EUR
(2): Volume: 100 Unit price: 46.7 EUR
(3): Volume: 200 Unit price: 46.7 EUR
(4): Volume: 6599 Unit price: 46.7 EUR
(5): Volume: 1596 Unit price: 46.7 EUR
(6): Volume: 329 Unit price: 46.6 EUR
Aggregated transactions (6):
Volume: 8829
Volume weighted average price: 46.69627 EUR
TURQUOISE (TRQX)
Transaction date: Not specified
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details:
(1): Volume: 15 Unit price: 46.66 EUR
Aggregated transactions (1):
Volume: 15
Volume weighted average price: 46.66 EUR
CCXE
Transaction date: Not specified
Instrument type: SHARE
ISIN: FI0009014377
Nature of transaction: DISPOSAL
Transaction details:
(1): Volume: 156 Unit price: 46.655 EUR
Aggregated transactions (1):
Volume: 156
Volume weighted average price: 46.655 EUR
About Orion Corporation
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture, and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases, and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
Frequently Asked Questions
What is the recent transaction reported by Orion Corporation?
The recent transaction involves significant disposals executed by CEO Liisa Hurme.
Who is Liisa Hurme?
Liisa Hurme is the Chief Executive Officer of Orion Corporation.
What type of securities were disposed of?
Shares of Orion Corporation were disposed of in the transactions mentioned.
What venues were involved in the transactions?
The transactions occurred on NASDAQ HELSINKI LTD, TURQUOISE, and CCXE.
How does Orion Corporation contribute to healthcare?
Orion develops and manufactures pharmaceuticals and health products, focusing on improving well-being for over a century.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.